trial

Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder

NCTId NCT00838227
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Manhattan Psychiatric Center
Primary completion 2012-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2008-02
Primary completion
2012-01
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
modafinil

Sponsors

Manhattan Psychiatric CenterLead Sponsor

Investigators

1
Jean-Pierre Lindenmayer, MDPrincipal Investigator

Sites

0 total

Linked catalysts

1
Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder — primary completion2012-01

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2012-01
Status
WITHDRAWN
relationships
The graph out of here
drug
modafinil
drug
lead_sponsor
Manhattan Psychiatric Center
company
indication
Schizophrenia
indication
Obesity
indication
Schizophrenia
indication
investigator
Jean-Pierre Lindenmayer, MD
person